DAILYPEPTIDE GUIDE
Experimental / RUO

Selank

TP-7

Selank is cataloged for research literacy, with a clear separation between proposed mechanisms, marketed claims and validated human evidence.

Compare
EvidenceTier 3
RegulatoryUnapproved / RUO
SafetyUncertain or Concerning
Clinical phaseNot FDA approved
01

Overview

ClassSynthetic tuftsin analogue
Sponsor / developerNo FDA-approved sponsor
Review statusDraft
Record IDPEP-053
02

Plain-language guide

What it was designed or studied for

Discussed or marketed in research-only contexts for Anxiety claims, Cognition claims. It is not approved for treating these uses.

How it works, simply

It interacts with a specific cell-signaling pathway. The measured clinical effect depends on the exact molecule, formulation, population and quality of evidence.

This simplified explanation is educational context, not a treatment recommendation or a substitute for the clinical evidence below.
03

Clinical mechanism

Proposed anxiolytic and immune effects have limited and geographically narrow human evidence.

Mechanism plausibility is not the same as demonstrated clinical benefit.
04

Applications

  • Anxiety claims
  • Cognition claims
05

Human evidence

Validated human efficacy evidence is absent, limited or not independently replicated.

Tier 3
06

Preclinical evidence

Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.

06

Regulatory status

Unapproved / RUO. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.

07

Safety

Uncertain or Concerning

  • Human safety data are incomplete
  • Product identity, sterility and dose consistency may be unknown
08

Interactions

Combination data are sparse. Absence of documented interaction evidence is not evidence of compatibility.

09

Treatment pattern

No validated human dosing or cycling protocol exists.

10

Manufacturing and quality

RUO and grey-market products may not establish identity, net content, sterility, endotoxin control or cold-chain integrity.

12

Sources

  1. 01
    Primary regulatory record

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  2. 02
    Clinical trial registry

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  3. 03
    Peer-reviewed literature

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

13

Gaps and unverified claims

  • No validated human dosing or cycling protocol exists.
  • Long-term safety and product-quality consistency remain unresolved.
14

Last reviewed

August 5, 2026 · Draft